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Abstract
Background
Lymphatic filariasis is caused by the parasitic wormsWuchereria bancrofti, Brugia malayi or
B. timori, which are transmitted via the bites from infected mosquitoes. Once in the human
body, the parasites develop into adult worms in the lymphatic vessels, causing severe dam-
age and swelling of the affected tissues. According to the World Health Organization, over
1.2 billion people in 58 countries are at risk of contracting lymphatic filariasis. Very few
drugs are available to treat patients infected with these parasites, and these have low effi-
cacy against the adult stages of the worms, which can live for 7–15 years in the human
body. The requirement for annual treatment increases the risk of drug-resistant worms
emerging, making it imperative to develop new drugs against these devastating diseases.
Methodology/Principal Findings
We have developed a yeast-based, high-throughput screening system whereby essential
yeast genes are replaced with their filarial or human counterparts. These strains are labeled
with different fluorescent proteins to allow the simultaneous monitoring of strains with para-
site or human genes in competition, and hence the identification of compounds that inhibit
the parasite target without affecting its human ortholog. We constructed yeast strains
expressing eight different Brugia malayi drug targets (as well as seven of their human coun-
terparts), and performed medium-throughput drug screens for compounds that specifically
inhibit the parasite enzymes. Using the Malaria Box collection (400 compounds), we identi-
fied nine filarial specific inhibitors and confirmed the antifilarial activity of five of these using
in vitro assays against Brugia pahangi.
Conclusions/Significance
We were able to functionally complement yeast deletions with eight different Brugia malayi
enzymes that represent potential drug targets. We demonstrated that our yeast-based
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004401 January 26, 2016 1 / 15
OPEN ACCESS
Citation: Bilsland E, Bean DM, Devaney E, Oliver
SG (2016) Yeast-Based High-Throughput Screens to
Identify Novel Compounds Active against Brugia
malayi. PLoS Negl Trop Dis 10(1): e0004401.
doi:10.1371/journal.pntd.0004401
Editor: Timothy G. Geary, McGill University,
CANADA
Received: August 14, 2015
Accepted: December 31, 2015
Published: January 26, 2016
Copyright: © 2016 Bilsland et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was financed by The Bill and
Melinda Gates Foundation (http://www.
gatesfoundation.org), with the Grand Challenges
Explorations grant OP1087646 to SGO and EB and
OPP1098441 to ED. It was also supported by the
São Paulo Research Foundation (http://www.fapesp.
br/en/), with grant 2015/19103-0 to EB. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
screening platform is efficient in identifying compounds that can discriminate between
human and filarial enzymes. Hence, we are confident that we can extend our efforts to the
construction of strains with further filarial targets (in particular for those species that cannot
be cultivated in the laboratory), and perform high-throughput drug screens to identify spe-
cific inhibitors of the parasite enzymes. By establishing synergistic collaborations with
researchers working directly on different parasitic worms, we aim to aid antihelmintic drug
development for both human and veterinary infections.
Author Summary
We have developed and validated a yeast-based high-throughput screening assay for the
identification of specific inhibitors of filarial targets. We engineered yeast strains to func-
tionally express parasite and human enzymes, labeling these with fluorescent proteins and
growing them in competition in the presence of test compounds. These strains express dif-
ferent target proteins from Brugia malayi (as well as their human orthologs) and our
results demonstrate that it is possible to identify compounds that can discriminate
between filarial and human enzymes. Accordingly, we are confident that we can extend
our assay to novel targets from Brugia malayi and other worms of medical and veterinary
importance, and perform high-throughput screens to identify new drugs against different
parasitic worms.
Introduction
Lymphatic filariasis is a neglected tropical disease caused primarily by the parasitic nematodes
Wuchereria bancrofti and Brugia malayi. The painful and disfiguring manifestations of this dis-
ease, also known as elephantiasis, can lead to permanent disability, causing an annual loss of
approximately 5.5 million disability adjusted life years, affecting the poorest populations in
Africa, Asia, and Latin America [1]. Current antifilarial therapies aim to eliminate filariasis
through mass drug administration. However, in standard doses, the drugs used for this purpose
(diethylcarbamazine, ivermectin and albendazole) are not effective against adult nematodes.
As the adult worms can live in the human body for ca. 15 years [2], patients need to undergo
multiple rounds of treatment, increasing not only the cost of therapy, but also the risk of drug-
resistant worms emerging [3–5].
Filarial worms are difficult to cultivate in vitro, so adult worms for laboratory studies have
to be obtained from animal models. Marcellino et al. [6] successfully developed a whole-plate,
motion-based screen for monitoring drug activity against macroscopic parasites (WormAssay).
This method was subsequently employed in screens against B.malayi [2], leading to the identi-
fication of the antifilarial activity of the FDA-approved drug auranofin. Unfortunately, there is
no small animal model for other filarial worms, such asW. bancrofti [7] or Onchocerca volvu-
lus; hence, there is a requirement for novel assays in the search for better treatments targeting
filariasis cell-based assays also require extensive optimization). An alternative to parasite-based
assays is to use in vitro drug screens based on protein targets. However, in vitro target-based
assays require careful (and costly) optimization of the screening platform for each individual
target protein to be tested, and provide no information on whether the drug is likely to be
taken up by cells or whether it has general cytotoxicity.
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To address these problems, we have developed and successfully validated a novel approach
to high-throughput screens (HTS) for antiparasitic compounds using yeast [8,9]. Yeast cul-
tures, which can be grown rapidly and at low cost, are ideal for use in automated screens [8–
11]. Yeast cells are suitable hosts for the expression of nematode proteins [12–18], including
enzymes essential for different life-cycle stages of the parasites, many of which cannot be prop-
agated in vitro [17]. We engineered Saccharomyces cerevisiae strains to express either different
parasite drug targets [9], or their equivalent human proteins, such that the growth of the yeast
is dependent on the functioning of these heterologous proteins. We then transformed the engi-
neered strains with plasmids expressing either CFP (cyan fluorescent protein), Venus (yellow
fluorescent protein), Sapphire (blue fluorescent protein) or mCherry (red fluorescent protein),
to enable their in vivo labeling.
Our engineered yeast strains are genetically identical, apart from expressing different heter-
ologous drug targets and fluorescent labels that allow the growth of multiple strains to be fol-
lowed in a single culture. These mixed cultures can be treated with chemical libraries to
identify compounds capable of specifically inhibiting strains with the parasite targets but not
their human counterparts. By these means, the drug sensitivity observed in a particular strain
can be directly linked to the in vivo inhibition of the heterologous target protein. This approach
has a number of significant advantages over conventional screens: it is very easy to set up for
different drug targets; it is cheap, as the volumes used are very small and the yeast growth
medium is inexpensive; it discriminates between compounds affecting parasite enzymes and
human enzymes, and, by definition, active compounds must be able to enter living cells.
In this work, we evaluated the potential of such yeast-based drug screens in the identifica-
tion of novel antifilarial compounds. We constructed yeast strains expressing different B.
malayi target proteins, and used them to screen for novel inhibitors of filarial enzymes. We uti-
lized a publicly available small-chemical library (400 Malarial Box compounds; http://www.
mmv.org/malariabox) and identified compounds with significant inhibitory activity against the
B.malayi enzymes, but little or no detectable activity against the equivalent human enzymes
expressed in yeast. These first hit compounds were then validated in vitro against the closely
related species, Brugia pahangi (continuously cultivated in our laboratory) with encouraging
results, providing a proof of principle for this approach.
Methods
Ethics statement
All animal protocols were carried out in accordance with the guidelines of the UK Home
Office, under the Animal (Scientific Procedures) Act 1986, following approval by the Univer-
sity of Glasgow Ethical Review Panel. Experiments were performed under the authority of the
UK Home Office, project numbers 60/4448 and 60/3792.
Plasmid constructs
The filarial enzymes selected for testing are listed in Table 1. The coding regions of Bm1_22900
(BmNMT), Bm1_01925 (BmPGK), Bm1_29130 (BmTPI), Bm1_ 49000 (BmPIS), Bm1_48165
(BmSAH), Bm1_38705 (BmSEC53), Bm1_11585 (BmADE13) and Bm1_23075 (BmCDC8)
were PCR-amplified from an adult Brugia malayi cDNA library, kindly donated by the Filaria-
sis Research Reagent Resource Center (University of Georgia). These were cloned into the
BamHI-PstI sites of pCM188 [19] to produce pCMBmNMT, pCMBmPGK, pCMBmTPI,
pCMBmPIS, pCMBmSAH, pCMBmSEC53, pCMBmADE13 and pCMBmCDC8. These con-
structs placed the heterologous genes under the control of the TetO2 promoter. Synthetic
genes encoding Brugia malayi Bm1_33465 (BmCDC21), Bm1_16500 (BmKRS), Bm1_42945
Yeast-Based Screens to Identify Novel Antifilarials
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(BmMVD), Bm1_57600 (BmRKI) and Bm1_16300 (BmDYS) were synthesized by Geneart and
sub-cloned into the BamHI-PstI sites of pCM188 [19] to produce pCMBmCDC21,
pCMBmKRS, pCMBmMVD, pCMBmRK1, and pCMBmDYS.
The coding regions of human TPI1 (HsTPI), CDIPT (HsPIS), AHCYL1 (HsSAHa), AHCY/
SAHH (HsSAHb), PMM2 (HsSEC53), PUR8 (HsADE13), CDC8/DTYMK (HsCDC8) and
PPA1 (HsIPP1a) were PCR amplified from a cerebellum cDNA library, kindly donated by Dr.
Nianshu Zhang (University of Cambridge). These were cloned into the BamHI-PstI sites of
pCM188 [19] to produce pCMHsTPI, pCMHsPIS, pCMHsSAHa, pCMHsSAHb,
pCMHsSEC53, pCMHsADE13, pCMHsCDC8 and pCMHsIPP1a. Synthetic genes encoding
Homo sapiens TYMS (HsCDC21), LysRS (HsKRS), MVD (HsMVD), and RPIA (HsRKI) were
synthesized by Geneart and sub-cloned into the BamHI-PstI sites of pCM188 [19] to produce
pCMHsCDC21, pCMHsKRS, pCMHsMVD, and pCMHsRK1. Plasmid maps for new con-
structs developed in this work are available in Figs A to AF in S1 Text. Plasmids encoding
human NMT2 and PGK1 (pCMHsNMT and pCMHsPGK) are described in Bilsland et al [9].
Yeast strains
PDR5 encodes the major drug export pump of Saccharomyces cerevisiae, hence we deleted
PDR5 in all of our yeast strains to increase their susceptibility to the test compounds. Deletion
of the yeast PDR5 coding sequence was performed as described previously [20].
pCMBmNMT constructs were transformed into nmt1Δ::KanMX/NMT1 pdr5Δ::HisMX/
PDR5 strains (BY4743 background [21]). pCMBmPGK constructs were transformed into
pgk1Δ::KanMX/PGK1 pdr5Δ::HisMX/PDR5 strains (BY4743 background). The same approach
(transformation of the heterologous construct into a yeast strain heterozygous for a deletion
Table 1. Targets selected for yeast-based screens.
Target protein Brugia
malayi
Wuchereria
bancrofti
Homo
sapiens
Functions Cognate
yeast gene
N-myristoyltransferase (NMT) Bm1_22900 WUBG_03313 O60551 Covalent attachment of myristic acid to the N-terminal
glycine residue of several proteins, cellular growth
and signal transduction
NMT1
phosphoglycerate kinase
(PGK)
Bm1_01925 WUBG_03621 P00558 Glycolysis, energy metabolism PGK1
triose-phosphate isomerase
(TPI)
Bm1_29130 WUBG_07449 P60174 Glycolysis, energy metabolism TPI1
adenosyl homocysteinase Bm1_48165 WUBG_05842 P23526 Cellular lipid homoeostasis SAH1
Inorganic pyrophosphatase Bm1_16955 WUBG_14547 Q15181 Rapid exchange of oxygen from Pi with water IPP1
Phospho mannomutase Bm1_38705 WUBG_05311 O15305 Folding and glycosylation of secretory proteins SEC53
thymidylate synthase Bm1_33465 WUBG_07963 P04818 Biosynthesis of pyrimidine deoxyribonucleotides CDC21
lysyl-tRNA synthetase Bm1_16500 WUBG_09456 Q15046 Protein synthesis KRS1
adenylosuccinate lyase Bm1_11585 WUBG_03558 P30566 Purine nucleotide biosynthesis ADE13
diphospho mevalonate
decarboxylase
Bm1_42945 WUBG_07413 P53602 Biosynthesis of isoprenoids and sterols MVD1
ribose-5-phosphate isomerase Bm1_57600 WUBG_03052 P49247 Pentose phosphate pathway RKI1
thymidylate kinase Bm1_23075 WUBG_02750 P23919 Biosynthesis of pyrimidine deoxyribonucleotides CDC8
deoxyhypusine synthase Bm1_16300 WUBG_02450 P49366 Hypusine biosynthesis DYS1
very-long-chain (3R)-
3-hydroxyacyl-CoA
dehydratase
Bm1_32340 WUBG_04779 Q6Y1H2 Sphingolipid biosynthesis and protein trafﬁcking PHS1
CDP-alcohol phosphatidyl
transferase
Bm1_49000 WUBG_00951 O14735 Biosynthesis of phosphatidylinositol (glycolipid anchors
for some of the plasma membrane proteins)
PIS1
doi:10.1371/journal.pntd.0004401.t001
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mutant of the orthologous yeast gene and heterozygous for pdr5) was employed for all subse-
quent constructs. Heterozygous strains harbouring the heterologous constructs were sporu-
lated and derived haploids were selected for growth assays and drug screens. Strain genotypes
are described in Table A in S1 Text.
Bioinformatics
Saccharomyces cerevisiae, Brugia malayi and Homo sapiens orthologues were selected based on
data available at: http://inparanoid.sbc.su.se/cgi-bin/index.cgi. Multiple protein sequence align-
ments were performed using https://www.ebi.ac.uk/Tools/msa/, creating a pairwise identity
matrix between each protein orthologue.
Growth assays
Yeast strains were grown in 2.5 mL YPD (1% yeast extract, 2% peptone, 2% glucose) cultures
overnight at 30°C. Cultures were diluted 100 times in fresh YPD with 0, 5 or 10 mg/L doxycy-
cline to tune-down the expression of the target protein from the TetO2 promoter. Clear
384-well plates (Corning) were then filled with 70 μL of each diluted culture (in triplicate).
Plates were incubated in a BMG Optima plate reader and OD595 measures for each culture
were acquired every 15 minutes. Growth scores were obtained by calculating the maximum
exponential growth rate for each culture, and then multiplying this value by the yield of the cul-
ture (yield = maximum OD595—minimum OD595). Growth scores of the yeast strains depen-
dent for growth on either the B.malayi or human coding sequence for the target enzyme were
divided by the score for the corresponding wild-type strains (BY4741 or BY4742), to estimate
their relative growth.
Drug screens
Yeast strains were transformed with fluorescent plasmids expressing one of the following fluo-
rescent proteins mCherry (yEp_Cherry_LEU2), Venus (yEp_venus_LEU2), Sapphire (yEp_-
sapphire_LEU2) or CFP (yEp_CFP_LEU2) [8]. This allowed us to monitor, in real time, the
growth of 2–4 different yeast strains growing in competition. Fluorescently labelled strains
were grown in 2.5 mL YNB (1, 7 g/l yeast nitrogen base, 5 g/L ammonium sulphate, 2% glucose,
and amino acid supplements) overnight at 30°C. Cultures were pooled and diluted 50 times in
fresh YNB. An aliquot (35 μL) of the diluted pooled-culture was added to each well of black
384-well plates, together with 35 μL of YNB with 20 μM of each test compound (final 70 μL of
1:100 cultures with 10 μM of the test compound). Each experiment was run in quadruplicate,
with two replicates using one combination of fluorescent markers, and two replicates using the
alternate combination, in order to minimize false-positive results. Plates were incubated in a
BMG Optima plate reader and fluorescence measured every 25 minutes, for 48 hours, in 4 dif-
ferent channels: Venus (excitation 500 nm/emission 540 nm), CFP (440 nm/490 nm), Sapphire
(405 nm/510 nm) and mCherry (580 nm/612 nm). We confirmed each of our hits by generat-
ing dose:response curves with 0, 2, 10 and 50 μM of each hit compound.
Curve fitting
Time-series fluorescence data from each channel was analyzed using a fitting procedure written
in R, based on the model-free spline method of Kahm et al. [22]. The first 26 fluorescence mea-
surements were used for analysis (corresponding to 26.66 hours of incubation); beyond this
time, fluorescence decayed due to photo-bleaching. Specifically, a smoothed spline was fitted to
the raw data for each channel and the first derivative through each point of the fit calculated.
Yeast-Based Screens to Identify Novel Antifilarials
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The highest derivative was taken as the maximum exponential growth rate (μ). This gradient
was extrapolated back towards the start of the growth curve by fitting a straight line of the form
y = mx + c. The lag phase duration (λ) was estimated by finding the intercept of this line and
the baseline fluorescence from the start of the experiment. The fluorescence yield was calcu-
lated by subtracting the baseline fluorescence from the maximum value of the fit. These param-
eters are summarized in Fig AG in S1 Text.
Normalization and scoring
Each compound was scored according to:
Score ¼ rate  yield
lag
The average score for each compound was normalized to the average score for the DMSO
control from the corresponding row in the plate. Compounds were scored for each pool
(marker swap) independently. A compound was considered a hit when the relative growth
score, in both marker combinations, of the recombinant strains expressing the parasite target
protein was significantly lower than the growth score of the strain expressing the human
enzyme.
Validation in Brugia pahangi
Female worms of B. pahangi were recovered from infected jirds (the rodent,Meriones unguicu-
latus) approximately four months post-infection, exactly as described previously [23]. Worms
were washed once in Hank’s Balanced Salt Solution and then cultured individually in 24-well
tissue culture plates containing 2.0 ml of RMPI-1640 (Invitrogen, Cat No: 52400) supple-
mented with 5% heat-inactivated fetal bovine serum, 1% glucose and 100 units per mL of peni-
cillin/streptomycin (all Invitrogen) for 24 hours to monitor viability and microfilarial output.
Healthy worms were then selected for drug testing. Initially, each compound was tested in trip-
licate at concentrations of 50 μM and 10 μM. Control wells contained the appropriate concen-
tration of the DMSO solvent. Parasites were also exposed to geldanamycin, a known Hsp90
inhibitor, at the same concentrations, as a positive control. All cultures were maintained at
37°C in 5% v/v CO2 in air and were monitored daily for viability. In a second experiment, adult
worms were exposed to a wider concentration range of three selected drugs that had proved
active in the first experiment. These were MMV396794, MMV665941 and MMV666022. Each
drug was tested in triplicate at 25, 10, 5 and 2.5 μM.
Results
Target selection
We initially selected 15 enzymes (Table 1) to test as anti-filarial targets according to the follow-
ing criteria: highly expressed in the adult stages of the parasite; likely to be essential for the via-
bility of the nematode in the human host; and have an essential yeast ortholog. As drugs such
as DEC and ivermectin have potent microfilaricidal activity, we chose to focus on adult para-
sites to control the stages not affected by current therapies. Furthermore, adult worms are the
cause of much of the pathology associated with lymphatic filariasis [24].
Cloning of the Brugia malayi targets and human counterparts
We obtainedWuchereria bancrofti and Brugia malayi cDNA libraries, prepared from mRNA
extracted from adult stages of the nematodes, from the Filariasis Research Reagent Resource
Yeast-Based Screens to Identify Novel Antifilarials
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Center (The University of Georgia). These cDNA libraries were used as templates for amplifi-
cation by polymerase chain reaction (PCR), and cloning into yeast plasmids.
From the outset of our work, we noticed that the publicly available genome sequence ofW.
bancrofti contains multiple gaps, which frequently overlapped with our target genes. This
made the design of primers for coding sequence (cds) amplification problematic. On the other
hand, the genome sequence of B.malayi is very well annotated, facilitating the cloning proce-
dure. Hence, we focused most of our cloning efforts on B.malayi targets. In spite of this, after
multiple attempts and primer designs, we failed to amplify seven of the intended B.malayi tar-
gets (Table 2). This was probably due to either the absence of that particular cDNA in the
libraries or to errors in the annotated sequence. The problem due to the low coverage of our
cDNA library was overcome by synthesizing DNA encoding each of the selected Brugia targets
to allow their expression in yeast. We identified two instances of errors in the published Brugia
genome sequence by either sequencing our clones derived from cDNA (BmSAH), or by pheno-
typing strains expressing a synthetic cds based on the predicted sequence of the BmMVD gene
product.
We observed that the synthetic human MVD could complement the yeast deletion very suc-
cessfully (88% of wild-type growth), whereas the synthetic B.malayiMVD could not. Align-
ment of the publicly available B.malayi, Loa loa (eye worm), human, and yeast sequences,
demonstrated that the B.malayi sequence diverged from those of the other three species,
strongly suggesting either a non-conserved insertion in the Brugia malayi protein (which leads
to the loss of function of the heterologous protein in yeast) or a problem with genome assembly
of the published B.malayi sequence (Fig 1).
Table 2. Brugia malayi drug targets. B.malayi targets selected for our screening pipeline (column 1); yeast and human orthologs (columns 2 and 3,
respectively); outcome of the cloning efforts of B.malayi (Bm) or human (Hs) genes (columns 4 and 5); outcome of the functional complementation in yeast
(columns 6 and 7), where % complementation = 100 * growth score of strains with the heterologous target/ growth score of wild-type strains; source of coding
region for each clone (column 8).
Brugia malayi Yeast Gene HumanGene Bm cloning Hs cloning Bm compl (%) Hs compl (%) OBS
Bm1_22900 NMT1 NMT2 Yes Yes Yes (96) Yes (100) cDNA
Bm1_01925 PGK1 PGK1 Yes Yes Yes (139.) Yes (110) cDNA
Bm1_29130 TPI1 TPI1 Yes Yes Yes (84) Yes (77) cDNA
Bm1_49000 PIS1 CDIPT Yes Yes Yes (86) Yes (98) cDNA
Bm1_48165 SAH1 AHCYL1 (A) Yes Yes Yes (83) Yes (103.) cDNA
Bm1_48165 SAH1 AHCY, SAHH (B) - Yes - Yes (88) cDNA
Bm1_48165 SAH1 AHCYL2 (C) - No - cDNA
Bm1_38705 SEC53 PMM2 Yes Yes No (0) No (0) cDNA
Bm1_11585 ADE13 ADSL Yes Yes No (0) No (0) cDNA
Bm1_23075 CDC8 CDC8, DTYMK Yes Yes No (0) Yes (72) cDNA
Bm1_16955 IPP1 PPA1 (A) No Yes Yes (82) cDNA
Bm1_16955 IPP1 PPA2 (B) - Yes - No (0) cDNA
Bm1_16955 IPP1 LHPP (C) - Yes - No (0) cDNA
Bm1_33465 CDC21 TYMS Yes Yes Yes (94) Yes (69) Synthetic
Bm1_16500 KRS1 KARS Yes Yes No (0) No (0) Synthetic
Bm1_42945 MVD1 MVD1 Yes Yes No (0) Yes (88) Synthetic
Bm1_57600 RKI1 RPIA Yes Yes Yes (78) Yes (117.) Synthetic
Bm1_16300 DYS1 DHPS Yes No Yes (91) - Synthetic
Bm1_32340 PHS1 PTPLa No Yes - No (0)
Bm1_32340 PHS1 PTPLb - No - -
doi:10.1371/journal.pntd.0004401.t002
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Similarly, sequencing of the cloned B.malayi adenosylhomocysteinase (Bm1_48165,
BmSAH), demonstrated an insertion of 27 amino-acids (aa) between aa 88 and 89 of
Bm1_48165. Eight independent BmSAH plasmids were constructed and sequenced and the
same insertion was always detected. As the same insertion is present in both yeast and human
SAH (Fig 2), it suggests that there may be an error in the B.malayi genome sequence, or that B.
malayi encodes more than one splice variant of the enzyme. Furthermore, the encoded protein
from our clone is enzymatically functional in yeast, complementing the deletion of the ortholo-
gous yeast gene.
Fig 1. CLUSTAL 2.1 multiple sequence alignment of diphosphomevalonate decarboxylases fromBrugia malayi (BmMVD), Loa loa (LlMVD),Homo
sapiens (HsMVD) and Saccharomyces cerevisiae (ScMVD), highlighting two regions in the published BmMVD sequences that diverge from the
consensus between the orthologous protein sequences. These could be due to the presence of different splice variants of the Brugia enzyme, natural
insertions or errors in the published sequence.* conserved residues;: chemically conserved changes;. non-conserved changes.
doi:10.1371/journal.pntd.0004401.g001
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We constructed seven additional strains where B.malayi gene products (Bm1_22900/
BmNMT, Bm1_01925/BmPGK, Bm1_29130/BmTPI, Bm1_49000/BmPIS, Bm1_33465/
BmCDC21, Bm1_57600/BmRKI, Bm1_16300/BmDYS) were able to complement the essential
functions of the yeast orthologous gene. The heterologous genes were cloned into the yeast
expression vectors under the regulation of the TetO2 promoter [25]. This promoter is constitu-
tively on; however, by adding doxycycline to the growth medium, it is possible to tune-down
the expression of the construct. Decreasing the expression of the target enzyme facilitates the
growth inhibition by the test compounds (less target = more efficient inhibition). We have pre-
viously tested the inhibition of expression from the TetO2 promoter by addition of 1, 2, 5, 10,
20, 50 or 100 mg/L of doxycycline [9] and found that 5 and 10 mg/L would be ideal for the cur-
rent work. Hence, we performed growth assays with each of the heterologous strains in
medium with 0, 5 or 10 mg/L of antibiotic (Fig 3). However, we noticed that most of our strains
require the full expression of the heterologous targets for optimum growth. Hence, drug
screens employing the strains expressing B.malayi targets were performed in the absence of
doxycycline.
Fig 2. Partial CLUSTAL 2.1 multiple sequence alignment of publicly availableBrugia malayi (Bm1_48165),Homo sapiens (HsSAH),
Saccharomyces cerevisiae (ScSAH), and our clonedBrugia malayi (BmSAH) S-adenosyl homocysteinases, showing the “insert”missing from the
publicly available nematode protein sequence. The absence of the 27 amino acids in the publicly available Brugia sequence (Bm1_48165) could indicate
a splice variant of the enzyme or simply a problem with the genome assembly.
doi:10.1371/journal.pntd.0004401.g002
Fig 3. Functional complementation of yeast deletions byBrugia malayi (Bm) orHomo sapiens (Hs) orthologous genes. Relative growth of yeast
strains expressing the parasite or human target compared to the growth of yeast strains expressing the native gene. Blue bars indicate the full expression of
the heterologous genes from the TetO2 promoter, and red and green bars indicate the growth of strains with a reduced expression of the essential enzyme.
doi:10.1371/journal.pntd.0004401.g003
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In addition to BmMVD, four other B.malayi clones constructed in our studies failed to
complement the essential functions of their cognate yeast genes; these were: Bm1_38705
(BmSEC53), Bm1_16500 (BmKRS1), Bm1_11585 (BmADE13) and Bm1_23075 (BmCDC8).
With a view to establishing a sequence-similarity cut-off on which to base the selection of new
targets, we calculated the percentage identity between yeast and filarial proteins that could suc-
cessfully replace each other and those that did not. We found no clear correlation between
sequence similarity and functional complementation; therefore, with the data collected so far,
we cannot predict which filarial enzymes will be functional in yeast (Fig 4).
Yeast screens established for five Brugia target proteins
The screening method developed in our laboratory allows the simultaneous screening of up to
three parasite targets and of the human counterpart in a single assay [8,9]. Hence, to make best
use of the screening efforts, we included yeast strains expressing Schistosoma mansoni PGK
[9], S.mansoni NMT [9],Homo sapiensNMT [9],H. sapiens PGK [9],H. sapiens TPI, H. sapi-
ens PIS andH. sapiens SAHa and SAHb (S1 Text). These eight strains, as well as the five strains
expressing the corresponding Brugia malayi targets (Table 2), were labeled by expression of
fluorescent proteins and screened against each of the 400 compounds from the Malaria
Box collection at a concentration of 10 μM. Comparing the growth of yeast strains expressing
either parasite or human enzymes, we identified a number of compounds that specifically
inhibited the growth of strains dependent on the parasite enzymes (Table 3). We then per-
formed dose:response experiments with 0, 2, 10 or 50 μM of each hit compound to confirm our
Fig 4. Scatter plot showing no correlation between the percentage identity between the human (Homo
sapiens) or Brugiamalayi proteins that do or do not complement the essential functions of the yeast
(Saccharomyces cerevisiae) orthologues. The average protein identity (in %) between heterologous
proteins able to complement the yeast deletions was 52.5 ± 10.6, whereas the identity between heterologous
proteins NOT able to complement the yeast deletions was 48.1 ± 10.0.
doi:10.1371/journal.pntd.0004401.g004
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NMT, PGK and PIS hits, and confirmed the specificity of the compounds at the indicated con-
centrations (Table 3, last column).
Validation of Brugia malayi hits in Brugia pahangi
We performed drug-sensitivity assays of our nine Brugia malayi hits using adult Brugia
pahangi worms. Two of the compounds were not soluble in the test conditions, but four of the
soluble compounds killed the worms at concentrations of 10 or 50 μM. Furthermore, the three
remaining compounds compromised the motility of B. pahangi (Fig 5). Of the four compounds
that had pronounced effects on adult worms at 24h incubation, two had immediate effects on
adult viability. For MMV396794 and MMV665941, adult worms were dead within 3h of incu-
bation at 50 μM concentration. These two compounds and MMV666022 were re-tested over a
wider range of concentrations starting at 25 μM. The results were very similar, with worms
incubated in MMVMMV396794 and MMV665941 at 25 μM dying within 3h of exposure. At
10 μM, all worms were dead in MMV665941 by 6h of exposure and at 5.0 and 2.5 μMwere
tightly coiled, although still motile at 6h, but dead by 24h. Compound MMV396794 killed all
worms at 10 μM by 24h, with worms at lower concentrations being sluggish at 24h, although
still alive. MMV666022 was the least active compound—although, after 48h, worms were
dying at 25 and 10 μM, they were largely unaffected at 5 or 2.5 μM. Considering that the com-
pounds used in our screens (Malaria Box) have low toxicity to human cells, this initial valida-
tion was extremely encouraging.
Discussion
We previously developed and validated an efficient high-throughput screening method for the
identification of compounds that selectively inhibit the activity of parasite proteins that are
candidate drug targets, but have little effect on the orthologous human proteins [8,9,11]. Most
of our initial screens were performed with targets from protozoan parasites (Plasmodium, Try-
panosoma, Leishmania) that are evolutionarily very distant from the human host. In the
Table 3. List of compounds that specifically inhibit the parasite targets at 10 μM: Bm = Brugia malayi, Sm = Schistosomamansoni, NMT = N-myris-
toyl transferase, PGK = phosphoglycerate kinase, PIS = inositol 3-phosphatidyltransferase, SAH = S-adenosylhomocysteinase. Smiles, or simpli-
fied molecular-input line-entry system, is a line notation for describing the structure of different chemical species. Ratio indicates the specificity of the
compound for the parasite target = growth score for yeast strains expressing the parasite enzyme/growth score for the yeast strains expressing the human
counterpart, Hence, a ratio of 1 indicates the absence of discrimination between parasite and human target, a ratio >1 indicates that the human enzyme is
inhibited more than the parasite enzyme, and a ratio <1 indicates a specific inhibition of the parasite target. The last column indicates the concentration
(in μM) in which the compounds specifically inhibited one or both of the parasite targets in dose-response experiments.
Malaria
Box compound
Smiles Target Ratio at 10
uM
Inhibition conﬁrmed at []
uM
MMV665941 CN(C)c1ccc(cc1)C(O)(c2ccc(cc2)N(C)C)c3ccc(cc3)N(C)C BmNMT/
SmNMT
0.17 10, 50
MMV009127 CC1CCN(Cc2c(O)ccc3C = C(C (= O)Oc23)c4nc5ccccc5s4)
CC1
BmPGK/
SmPGK
0.47 2, 10, 50
MMV666597 CCCCCCc1cc2C = C(C (= Nc3ccccc3C)Oc2cc1O)
c4nc5ccccc5[nH]4
BmPGK/
SmPGK
0.58 10, 50
MMV396797 n1(nc(C)c2c3ccc(OC)c(OC)c3)c2ncc(C#N)c1N BmPIS 0.74 50
MMV011259 n1(n2)c(nc(C)cc1Nc(cc(C)cc3C)c3)nc2C(F)(F)F BmSAH 0.51 -
MMV665843 Oc1c2CCCCc2nc3ccccc13 BmSAH 0.84 -
MMV666022 COc1ccc(cc1)C (= O)NC(c2ccccc2Cl)c3cc(Cl)c4cccnc4c3O BmSAH 0.77 -
MMV006706 n1(c2c(cccc2)n3)c3c(C#N)c(C)cc1N(CC4)CCN4C5CCCC5 BmSAH 0.85 -
MMV396794 c1(Cl)c(ccc(Cl)c1)OCC(O)CNC(C)(C)CC(C)(C)C BmSAH 0.88
doi:10.1371/journal.pntd.0004401.t003
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Fig 5. Validation of the hit compounds usingBrugia pahangi adult female worms.Chemical structures were obtained from www.chemspider.com. The
IC50 for each of the compounds in human fibroblasts (MRC5) is shown in the last column [26]. The IC50 of Geldanamycin against different human cell lines is
a consensus of multiple data available in the literature (www.medchemexpress.com/Geldanamycin.html).
doi:10.1371/journal.pntd.0004401.g005
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present work, we evaluated the suitability of our approach for identifying inhibitors of enzymes
from a metazoan animal, the nematode B.malayi.
Our assay is based on replacing essential yeast genes with their parasite or human counter-
parts, to allow the identification of compounds that inhibit the growth of yeast cells expressing
the parasite target but not the growth of yeast strains expressing their human counterpart. This
discrimination is very efficient for targets from parasites that are only distantly related to
humans. Therefore, at the outset of our studies, we were unsure as to whether we would iden-
tify any compound capable of inhibiting metazoan targets such as Brugia, without also inhibit-
ing the human ortholog.
Through the construction of yeast strains expressing the heterologous drug targets, we iden-
tified two instances where the publicly available B.malayi protein sequences are incorrect
(Bm1_48165 and Bm1_42945), and have made a small contribution towards improving the
annotation of the parasite genome. We also created tools for further studies of the functions of
eight different Brugia enzymes.
It was gratifying to note that even working with a small library of compounds (400 Malaria
Box drugs), it was possible to find compounds that could discriminate between human and
metazoan pathogen enzymes. Most importantly, the compounds identified in our yeast-based
screens can kill Brugia parasites in vitro, or inhibit their motility. Further studies will be neces-
sary to follow up on these findings and titrate minimal effective concentrations of drug with
activity against adult filarial worms. Interestingly, inhibition of filarial NMT proved to be very
effective in our screen, confirming previous data of Galvin et al [27]. In that study, NMT was
shown to be essential for viability in both B.malayi and in the free-living model nematode Cae-
norhabditis elegans. Hence, we are confident of the potential of our approach in pre-selecting
novel compounds against metazoan parasites, and will be able to extend our screens to targets
from other parasitic nematode species. Recent studies on the systematic humanization of yeast
strains [28] will be particularly helpfully in suggesting proteins that can successfully comple-
ment essential yeast deletions.
In conclusion, our yeast-based screen offers many advantages over organism-based screens
as a first pass for identifying compounds with activity against key filarial targets. Future studies
will screen for inhibitors of additional essential targets, and extend the screens to larger chemi-
cal libraries in the search for much-needed novel nematicides.
Accession numbers/ID numbers for Brugia malayi targets used in this
study
Bm1_22900, Bm1_01925, Bm1_29130, Bm1_48165, Bm1_16955, Bm1_38705, Bm1_33465,
Bm1_16500, Bm1_11585, Bm1_42945, Bm1_57600, Bm1_23075, Bm1_16300, Bm1_32340,
Bm1_49000.
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